Loading...
research article
Evaluation of the safety of intravesical BCG therapy in France: analysis of serious adverse events notified over a three-year period
2001
Objectives: Intravesical BCG therapy remains the first-line prophylactic treatment for recurrences of superficial bladder tumours. However necessary the safety, of this medicinal product, for which a potential risk of complications was demonstrated during development, needs to be evaluated.
Type
research article
Web of Science ID
WOS:000170184300010
Authors
Publication date
2001
Published in
Volume
11
Start page
458
End page
465
Peer reviewed
REVIEWED
EPFL units
Available on Infoscience
September 29, 2011
Use this identifier to reference this record